SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform

Impact · against what's priced in

The updates for SABS and Healios are largely operational progress reports that reinforce existing trial and manufacturing trajectories without introducing surprising catalysts. SABS's progress in Type 1 diabetes and Healios's Japanese regulatory path remain positive but incrementally evolve from previously known milestones.

SABS+0.40

No priced-in read yet